FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	DC	20549
vvasimigton,	D.O.	20070

STATEMENT OF CH	ANGES IN BENEFICIAL	OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average I	ourden									
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 Instruction 1(b)

Cloghe (Last)	ssy Paula (Fi		(Middle)		2. Issuer Name and Ticker or Trading Symbol Seres Therapeutics, Inc. [ MCRB ]  3. Date of Earliest Transaction (Month/Day/Year) 02/03/2023						(Ch	Relationship of Reporting Person(s) to Issuer Check all applicable)  Director 10% Owner  X Officer (give title Other (specify below)  See Remarks						
200 SIDI (Street) CAMBR (City)			02139 (Zip)		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	ndividual or Joint/Group Filing (Check Applicable c)  X Form filed by One Reporting Person Form filed by More than One Reporting Person				n	
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transa Date (Month/D				action	2A. Deemed Execution Date,			3. Transaci Code (In				ed (A) or	or 5. Amount of		Form: Direct (D) or Indirect		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
						V Amount (A) or (D) Price Transaction(s) (Instr. 3 and 4)  Ive Securities Acquired, Disposed of, or Beneficially Owned Its, calls, warrants, options, convertible securities)						(11311. 4)						
1. Title of Derivative Security (Instr. 3)	1. Title of 2. 3. Transaction Date Security or Exercise (Month/Day/Year) if any		ransac	5. Number 6. Date Exercisable and 7. Title and Am of Expiration Date of Securities					d Amount ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)				
				C	Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares					
Restricted Stock Units	(1)	02/03/2023			A		47,500		(2)		(2)	Common Stock	47,500	\$0.00	47,50	0	D	
Stock Option (Right to Buy)	\$5.5	02/03/2023			A		95,000		(3)	0.	2/02/2033	Common Stock	95,000	\$0.00	95,00	0	D	

## Explanation of Responses:

- 1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- 2. The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments
- 3. The option will vest as to 25% of the shares on February 3, 2024. The remainder of the shares will vest in 12 equal quarterly installments thereafter.

## Remarks:

Executive Vice President, Chief People Officer

/s/ Thomas J. DesRosier, 02/07/2023 attorney-in-fact for Paula Cloghessy

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.